Catalyst Pharmaceuticals, Inc.
CPRXCatalyst Pharmaceuticals, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is already 13 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (13 weeks in) while the P/E sits at the 54th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +0.0% year on year, and 134% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Catalyst Pharmaceuticals, Inc. trades at $31.5, in a confirmed uptrend and 13 weeks into that stage. That is +24.2% against its own 200-day average. It sits at 100% of a 52-week range of $20 to $32. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 20 straight weeks.
Today the stock is in a confirmed uptrend — week 13 of stage 2. At $31.5 it trades +24.2% versus its 200-day average and sits at 100% of its 52-week range ($20–$32).
Against the market, two honest reads. Cumulative: over the last 10.0 years the stock moved +3,836% while the S&P 500 moved +250% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 20 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Catalyst Pharmaceuticals, Inc. trades at 18.2× P/E, mid-range by its own standards (54th percentile). Its long-run median P/E is 18.1×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 18.2× is mid-range by its own standards (54th percentile), against a long-run median of 18.1× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +28.2% against a +44.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +34.8%/yr price move, ~+20.3%/yr came from earnings growth and ~+14.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Catalyst Pharmaceuticals, Inc. reads as topping out on its fundamental arc. Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +84.2% at its peak → +13.2% latest) while ROCE still reads 29.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +20.4% | +41.1% | — | — |
| Profit | +31.3% | +37.9% | — | — |
| EPS | +28.2% | +30.8% | — | — |
| Stock price | +44.4% | +34.8% | +41.5% | +44.7% |
4-Factor Sector Score
No sector-relative score — Catalyst Pharmaceuticals, Inc. is not among the largest members shown in this industry comparison for Biotechnology.
The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Catalyst Pharmaceuticals, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +7.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 43.3% a year. The last full year, FY25, came in at $0.6 B. The last four reported quarters add to $0.6 B.
FY25 revenue came in at $0.6 B (+20.4% on the year), capping 4 years at 43.3% compound. The latest quarter (Mar 26) printed $0.1 B, +7.1% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.7% growth against the decade's 43.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +13.2% over the last 4 quarters against +21.0%/yr over the last 8 — rolling over; TTM profit +5.0% vs +87.1%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Catalyst Pharmaceuticals, Inc.'s operating margin is 46.7% in the Mar 26 quarter, +3.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 22.5% to 47.6%. The current quarter sits inside that band.
The latest quarter's operating margin is 46.7%, +3.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 22.5%–47.6%.
Why the margin moved: operating margin went +3.8 pp year on year while gross margin went +1.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Catalyst Pharmaceuticals, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The 4-year compound rate is 51.4%. That is 40.0% of the quarter's revenue. The same quarter a year earlier earned $0.1 B. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.1 B, +0.0% year on year. On the full year, FY25 printed $0.2 B (+31.3%), and the 4-year compound rate is 51.4%.
🚨 Why profit moved: revenue contributed +7.1% and the margin +3.8 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +8.3% vs revenue +13.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 134% of Catalyst Pharmaceuticals, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.2 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.2 B was left as free cash.
FY25: operating cash of $0.2 B against reported profit of $0.2 B, leaving free cash of $0.2 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 134% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Catalyst Pharmaceuticals, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Catalyst Pharmaceuticals, Inc. earns a ROE of 22% in FY25. That is up from a trough of 18% in FY23. Return on invested capital clears the cost of that capital by +70.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 35.6% net margin on 0.54× asset turns.
FY25 ROE is 22%, recovered from a FY23 trough of 18% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 35.6% net margin × 0.54× asset turns × 1.16× balance-sheet leverage ≈ 22.3% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 78.8% − 8.3% = a +70.5 pp spread. The 8.3% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Catalyst Pharmaceuticals, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Catalyst Pharmaceuticals, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Catalyst Pharmaceuticals, Inc. carries total debt of $0.0 B against shareholder equity of $1.0 B as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.00 in FY21 to 0.00 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of $0.0 B against shareholder equity of $1.0 B — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.00 (FY21) to 0.00 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
6.8% of Catalyst Pharmaceuticals, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 4.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 6.8% of the float is sold short, and at typical trading volumes it would take about 4.1 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Catalyst Pharmaceuticals, Inc.: the Z-score reads 15.04. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 15.04 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 15.04.
No sector comparison is shown here — not among the largest members shown in this industry comparison.
Frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s stock price today?
Catalyst Pharmaceuticals, Inc. trades at $31.5, +44.4% over the past year. The company is valued at $4.0 B. The stock sits at 100% of its 52-week range of $20–$32, +24.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 5 August 2026.
What were Catalyst Pharmaceuticals, Inc.'s latest quarterly results?
Catalyst Pharmaceuticals, Inc. reported revenue of $0.1 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 7.1% and profit rose 0.0% year on year. Earnings per share were $0.50. The operating margin was 46.7%, 3.8 pp higher than a year earlier. — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s revenue?
Catalyst Pharmaceuticals, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +7.1% year on year. For the full FY25 fiscal year, revenue was $0.6 B (+20.4%). Over the last 4 years revenue compounded at 43.3% a year. — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s profit?
Catalyst Pharmaceuticals, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The operating margin ran 46.7% in the latest quarter. — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s market cap?
Catalyst Pharmaceuticals, Inc.'s market capitalisation is $4.0 B at a stock price of $31.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s P/E ratio?
Catalyst Pharmaceuticals, Inc. trades at a P/E of 18.2×, at the 54th percentile of its own 4-year range, against a long-run median of 18.1×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Catalyst Pharmaceuticals, Inc. pay a dividend?
No — Catalyst Pharmaceuticals, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc. overvalued?
On its own history, Catalyst Pharmaceuticals, Inc. looks mid-range against its own history: its P/E of 18.2× sits at the 54th percentile of its 4-year range (long-run median 18.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc. growing?
Yes — Catalyst Pharmaceuticals, Inc. is growing: latest-quarter revenue +7.1% year on year, profit +0.0%, and the margin +3.8 pp at 46.7%. The 4-year compound rates are 43.3% (revenue) and 51.4% (profit). The earnings engine currently reads: improving — as of 5 August 2026.
How is Catalyst Pharmaceuticals, Inc. performing?
Catalyst Pharmaceuticals, Inc. is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 7.1% and profit rose 0.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 20 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Catalyst Pharmaceuticals, Inc. in?
Topping out — revenue, profit and EPS growth have decelerated hard (revenue growth +84.2% at its peak → +13.2% latest) while ROCE still reads 29.7%. The read comes from the last 12 quarters of growth (revenue growth +13.2% latest, profit growth +5.0% latest, eps growth +10.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +24.2% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc. beating the market?
On recent form, yes — Catalyst Pharmaceuticals, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 20 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.0 years the stock moved +3,836% against the S&P 500's +250% — ahead of the index over the full window. — as of 5 August 2026.
Will Catalyst Pharmaceuticals, Inc.'s stock price go up?
This page publishes no price forecast for Catalyst Pharmaceuticals, Inc. What it measures instead: the stock price is $31.5, the price is in a confirmed uptrend 13 weeks in. Its P/E of 18.2× sits at the 54th percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against Catalyst Pharmaceuticals, Inc.?
Somewhat — short interest is 6.8% of Catalyst Pharmaceuticals, Inc.'s tradable float, about 4.1 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s capex?
Catalyst Pharmaceuticals, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Catalyst Pharmaceuticals, Inc.'s cash flow?
Catalyst Pharmaceuticals, Inc. generated $0.2 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 134% of Catalyst Pharmaceuticals, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.2 B against reported profit of $0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Catalyst Pharmaceuticals, Inc.?
On the balance sheet, the Z-score reads 15.04 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Catalyst Pharmaceuticals, Inc. in its business cycle?
Catalyst Pharmaceuticals, Inc.'s FY25 operating margin was 44.1%, against a 5-year band of 22.5%–47.6%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 46.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Catalyst Pharmaceuticals, Inc. story?
Biggest watch item: the price is already 13 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Catalyst Pharmaceuticals, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Catalyst Pharmaceuticals, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.